Erythropoietin for acute multiple sclerosis in patients with optic neuritis as a first demyelination event

To investigate the safety, tolerability, and short-term efficacy of treatment with erythropoietin in patients with optic neuritis as a first demyelination event. We conducted this randomized double-blind pilot study in the Shiraz University of Medical Sciences, Shiraz, Iran, from March 2007 to Janua...

Full description

Saved in:

Bibliographic Details
Published in:	Neurosciences (Riyadh, Saudi Arabia) Vol. 17; no. 2; pp. 151 - 155
Main Authors:	Borhani-Haghighi, Afshin, Ghodsi, Maryam, Razeghinejad, Mohammad R, Mardani, Samira, Mardani, Mohsen, Nikseresht, Ali R, Safari, Anahid, Bagheri, Mohammad H
Format:	Journal Article
Language:	English
Published:	Saudi Arabia 01-04-2012
Subjects:	Acute Disease Adolescent Adult Demyelinating Diseases - drug therapy Demyelinating Diseases - pathology Drug Therapy, Combination Erythropoietin - administration & dosage Erythropoietin - adverse effects Female Follow-Up Studies Glucocorticoids - administration & dosage Humans Magnetic Resonance Imaging Middle Aged Multiple Sclerosis - drug therapy Multiple Sclerosis - pathology Optic Neuritis - drug therapy Optic Neuritis - pathology Pilot Projects Prednisolone - administration & dosage Severity of Illness Index Treatment Outcome Young Adult
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	To investigate the safety, tolerability, and short-term efficacy of treatment with erythropoietin in patients with optic neuritis as a first demyelination event. We conducted this randomized double-blind pilot study in the Shiraz University of Medical Sciences, Shiraz, Iran, from March 2007 to January 2009. The participants were patients aged 18-45 years with optic neuritis and at least 3 hyperintense lesions on T2-weighted and FLAIR MRI, but no clinically definite multiple sclerosis (MS). They were randomized into 2 groups. The case group (5 patients) received intravenous methyl prednisolone (1000 mg/24 hours) and intravenous erythropoietin (20,000 unit/24 hours) for 5 consecutive days, and the control group (5 patients) received intravenous methyl prednisolone at the same dose as the case group, and a placebo. The groups were followed for one year and compared for adherence to protocol, adverse drug effects, mean duration of conversion to clinically definite MS, and MRI changes. All patients tolerated the protocol. One patient who received erythropoietin developed cerebral venous sinus thrombosis and anti-cardiolipin antibody positivity. One patient in the control group, but no patients in the case group, fulfilled the McDonald criteria for MS during the follow-up period, but none of the participants in either group developed clinically definite MS according to the Poser criteria. Erythropoietin may be effective, but should be used with caution.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-News-1 ObjectType-Feature-3 content type line 23
ISSN:	1319-6138